Key Stats for Bristol-Myers Squibb Stock
- Past-Week Performance: 3%
- 52-week Range: $43 to $63
- Valuation Model Target Price: $61
- Implied Upside: 11.5% over 1.9 years
Value your favorite stocks like Bristol-Myers Squibb with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Bristol-Myers Squibb Company stock rose about 3% over the past week, trading higher across most sessions and finishing near $56, close to the upper end of its recent short-term range.
The move followed a quiet stretch, with shares stabilizing above recent lows.
The stock moved higher as investors reacted to continued buying from large institutional holders, which reinforced confidence that downside risk is supported at current levels.
Recent filings showed Vanguard Group increased its stake by 1.8% and Charles Schwab Investment Management raised its position by 16.8%, signaling growing conviction from long-term investors even as the company navigates patent expirations and slower revenue growth.
Additional institutional activity added support, with Geode Capital Management increasing its holdings, Ameriprise Financial adding shares, and Norges Bank initiating a new stake worth about $1.6 billion.
In total, institutional investors and hedge funds now control about 76% of Bristol-Myers Squibb’s shares, highlighting strong sponsorship despite the stock trading below its 52-week high of roughly $63.
Overall, the weekly gain reflected valuation-driven buying backed by institutional accumulation rather than a reaction to a single headline.
The move showed how ownership data and perceived downside support can help Bristol-Myers Squibb shares grind higher as the market looks ahead to upcoming earnings and further updates on the company’s strategy.
See analysts’ growth forecasts and price targets for Bristol-Myers Squibb (It’s free) >>>
Is Bristol-Myers Squibb Undervalued?
Under valuation model assumptions, the stock is modeled using:
- Revenue Growth (CAGR): (3.6%)
- Operating Margins: 33.9
- Exit P/E Multiple: 10.0x
Based on these inputs, the model estimates a target price of $61, implying 11.5% total upside from recent levels over the next 1.9 years.
Over the next year, results are likely shaped by how effectively Bristol-Myers offsets revenue pressure from key drug losses through cost controls, pipeline execution, and contributions from newer therapies.
Margin performance remains a key support, since disciplined expense management and manufacturing efficiency continue to underpin solid operating profitability even as the top line comes under pressure.
Pipeline milestones and regulatory decisions across oncology, immunology, and cardiovascular programs will remain important signals for whether Bristol-Myers can stabilize and eventually return to growth.
Free cash flow durability also matters, as the company works to support its dividend and manage leverage following recent acquisitions.
Bristol-Myers Squibb appears undervalued at current levels, with upside tied less to a big valuation reset and more to steady execution on margins, pipeline progress, and cash generation over the next few years.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
